Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan A Grupp

Showing results (151-160 of 238) with videos related to

Pageof 24
Sort By:
Hemasphere|April 10, 2026
Preinfusion risk factors for the development of severe neurotoxicity following CART therapy in pediatric patientsCaroline Diorio, Regina M Myers, Yimei Li, et al.
Blood Advances|August 26, 2025
Improvements in Health-Related Quality of Life in Patients with Severe Sickle Cell Disease After Exagamglogene AutotemcelAkshay Sharma, Franco Locatelli, Monica Bhatia, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 2, 2014
TNF-receptor inhibitor therapy for the treatment of children with idiopathic pneumonia syndrome. A joint Pediatric Blood and Marrow Transplant Consortium and Children's Oncology Group Study (ASCT0521)Gregory A Yanik, Stephan A Grupp, Michael A Pulsipher, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 26, 2019
Partially CD3<sup>+</sup>-Depleted Unrelated and Haploidentical Donor Peripheral Stem Cell Transplantation Has Favorable Graft-versus-Host Disease and Survival Rates in Pediatric Hematologic MalignancyAlix E Seif, Yimei Li, Dimitri S Monos, et al.
Blood|June 5, 2015
Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoproteinHaiying Qin, Monica Cho, Waleed Haso, et al.
Pediatric Blood & Cancer|March 13, 2018
Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group studyChristopher C Dvorak, Prakash Satwani, Elliot Stieglitz, et al.
The Journal of Clinical Investigation|December 18, 2019
CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integrationChristopher L Nobles, Scott Sherrill-Mix, John K Everett, et al.
Leukemia|October 9, 2019
Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19Mukta Asnani, Katharina E Hayer, Ammar S Naqvi, et al.
The Lancet. Oncology|July 30, 2013
Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trialSusan G Kreissman, Robert C Seeger, Katherine K Matthay, et al.
Blood Advances|June 24, 2025
Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCLRakesh Awasthi, Stephan A Grupp, Edward R Waldron, et al.
Pageof 24

Showing results (151-160 of 238) with videos related to

Sort By:
Pageof 24
Hemasphere|April 10, 2026
Preinfusion risk factors for the development of severe neurotoxicity following CART therapy in pediatric patientsCaroline Diorio, Regina M Myers, Yimei Li, et al.
Blood Advances|August 26, 2025
Improvements in Health-Related Quality of Life in Patients with Severe Sickle Cell Disease After Exagamglogene AutotemcelAkshay Sharma, Franco Locatelli, Monica Bhatia, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 2, 2014
TNF-receptor inhibitor therapy for the treatment of children with idiopathic pneumonia syndrome. A joint Pediatric Blood and Marrow Transplant Consortium and Children's Oncology Group Study (ASCT0521)Gregory A Yanik, Stephan A Grupp, Michael A Pulsipher, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 26, 2019
Partially CD3<sup>+</sup>-Depleted Unrelated and Haploidentical Donor Peripheral Stem Cell Transplantation Has Favorable Graft-versus-Host Disease and Survival Rates in Pediatric Hematologic MalignancyAlix E Seif, Yimei Li, Dimitri S Monos, et al.
Blood|June 5, 2015
Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoproteinHaiying Qin, Monica Cho, Waleed Haso, et al.
Pediatric Blood & Cancer|March 13, 2018
Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group studyChristopher C Dvorak, Prakash Satwani, Elliot Stieglitz, et al.
The Journal of Clinical Investigation|December 18, 2019
CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integrationChristopher L Nobles, Scott Sherrill-Mix, John K Everett, et al.
Leukemia|October 9, 2019
Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19Mukta Asnani, Katharina E Hayer, Ammar S Naqvi, et al.
The Lancet. Oncology|July 30, 2013
Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trialSusan G Kreissman, Robert C Seeger, Katherine K Matthay, et al.
Blood Advances|June 24, 2025
Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCLRakesh Awasthi, Stephan A Grupp, Edward R Waldron, et al.
Pageof 24